A Futility Call Ends argenx’s Sjögren’s Phase 3
A Futility Call Ends argenx’s Sjögren’s Phase 3
argenx has decided to discontinue its Phase 3 UNITY study of efgartigimod in adults with moderate-to-severe Sjögren’s disease after an interim analysis indicated that the trial was unlikely to meet its primary endpoint. The decision marks a setback for the company’s efforts to expand its immunology portfolio into a disease area where patients continue to face significant treatment challenges.
Announced on October 8, 2026, the decision followed a recommendation from an Independent Data Monitoring Committee. The company said the treatment’s safety profile remained consistent with previous findings and that no new safety signals had been identified. citeturn395248search1turn395248news14
Why argenx Is Discontinuing the UNITY Study
Following an interim review, the independent monitoring committee concluded that the study was unlikely to achieve its primary endpoint. The committee therefore recommended stopping the trial for futility, leading argenx to discontinue the study.
In clinical development, a futility assessment helps determine whether a trial is likely to demonstrate the intended benefit if it continues. Such decisions can prevent patients from remaining in studies that are unlikely to produce a meaningful result.
The company plans to conduct a comprehensive analysis after the study closes and the database is locked. The analysis is intended to help researchers understand the outcome and identify insights that may support future research into Sjögren’s disease. citeturn395248search0
What the UNITY Trial Was Designed to Measure
UNITY was a Phase 3, randomized, double-blind, placebo-controlled, multicenter study with an open-label extension. Participants were assigned to receive either weekly subcutaneous efgartigimod or a placebo during the blinded treatment period.
The primary endpoint measured the change from baseline in systemic disease activity at Week 48, using the clinical EULAR Sjögren’s Syndrome Disease Activity Index, known as clinESSDAI.
The study enrolled adults who met established classification criteria for primary Sjögren’s disease, tested positive for anti-Ro/SSA autoantibodies and had moderate-to-severe systemic disease activity while receiving stable standard care.
Secondary measures included the proportion of participants achieving low disease activity, response according to the Sjögren’s Tool for Assessing Response (STAR), changes in patient-reported symptoms and treatment safety and tolerability. citeturn395248search1
Efgartigimod’s Earlier Research Raised Expectations
The Phase 3 setback follows earlier research that had encouraged further investigation of efgartigimod in Sjögren’s disease.
In 2025, argenx reported Phase 2 RHO study findings that suggested potential clinical activity. The company subsequently continued development through the larger UNITY trial, designed to evaluate whether the treatment could demonstrate efficacy in a broader clinical study.
However, encouraging findings in an earlier-stage trial do not guarantee success in Phase 3. Differences in study size, patient characteristics, treatment response and endpoint performance can affect whether an initial signal is confirmed.
The UNITY outcome highlights the difficulty of developing treatments for complex autoimmune diseases, where symptoms and systemic disease activity can vary considerably between patients. citeturn395248search11turn395248news6
No New Safety Signals Reported
argenx said the decision to stop UNITY was based on the assessment of efficacy prospects rather than a newly identified safety concern.
According to the company, safety remained consistent with efgartigimod’s established profile, and no new safety signals were identified in the interim review.
This distinction is important: a futility decision does not necessarily mean a drug has been found unsafe. Instead, it indicates that the available evidence suggests the study is unlikely to demonstrate the required benefit.
The decision concerns the development of efgartigimod for Sjögren’s disease. It should not be interpreted as a withdrawal of the medicine from its other approved uses. Patients receiving prescribed treatment should consult their healthcare professionals before making any changes to their medication.
What the Decision Means for Sjögren’s Disease Research
Sjögren’s disease is a chronic autoimmune condition that primarily affects moisture-producing glands, often causing dry eyes and dry mouth. It can also involve other organs and body systems, alongside symptoms such as fatigue and joint pain.
The condition’s varied presentation and systemic effects make the development of effective treatments challenging. While symptom management and existing care strategies can help patients, researchers continue to investigate therapies that may address underlying disease activity.
The discontinuation of UNITY removes one investigational programme from the near-term development landscape for Sjögren’s disease. However, it does not mean research into the condition has ended. Other therapeutic approaches remain under investigation, although their clinical progress and regulatory status differ.
For argenx, the next step is to examine the UNITY data in detail and determine what the findings reveal about efgartigimod’s performance in this disease. The company has said it intends to share learnings with the Sjögren’s community.
Implications for the Biopharmaceutical Industry
The UNITY decision illustrates the uncertainty associated with late-stage clinical development. A Phase 3 trial can require substantial investment and years of research, yet an interim assessment may lead a sponsor to stop a programme before its planned completion.
For biopharmaceutical companies, these decisions can affect development priorities, expected commercial opportunities and the allocation of research resources. They also reinforce the importance of carefully selecting clinical endpoints and understanding disease biology before advancing a candidate into large-scale trials.
For patients and clinicians, the outcome is a reminder that promising early-stage findings must be confirmed through robust clinical evidence before an investigational treatment can become an established therapeutic option.
argenx’s planned analysis of the UNITY results may provide further information about the trial’s outcome and help inform future investigations into Sjögren’s disease.
Sources:
Agar (E406)
Found this useful?
